The evidence indicates that most gastrointestinal adverse events occur within 2 to 8 weeks after the start of therapy, coinciding with the dose escalation process
The medication will keep therapeutic levels in your body in between doses, so you should be able to maintain appetite control throughout the week
Most Common Side Effects: Just like other GLP-1 medications, gastrointestinal issues were the most common: Nausea (especially during dose increases) Diarrhea Vomiting Constipation Abdominal pain The frequency: Higher with 8 mg and 12 mg doses compared to lower doses
Body fat distribution changes differ, with men seeing more concentrated midsection reduction and women experiencing more distributed fat loss
Phase 3 TRIUMPH-1 NCT05929066, TRIUMPH-2 NCT05929079, TRIUMPH-3 NCT05882045, TRIUMPH-4 NCT05931367, TRIUMPH-Outcomes NCT06383390
Unraveling the bioactivity of anticancer peptides as deduced from machine learning